TD Cowen Issues Positive Forecast for KindlyMD (NASDAQ:NAKA) Stock Price

KindlyMD (NASDAQ:NAKA) had its price objective boosted by TD Cowen from $1.00 to $17.00 in a research note released on Monday,Benzinga reports. TD Cowen currently has a buy rating on the stock.

A number of other equities research analysts have also commented on the stock. Weiss Ratings upgraded shares of KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a report on Saturday, May 23rd. Finally, Maxim Group decreased their price objective on shares of KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $22.33.

KindlyMD Price Performance

Shares of KindlyMD stock opened at $4.69 on Monday. KindlyMD has a one year low of $3.33 and a one year high of $659.20. The business’s 50 day simple moving average is $4.65 and its two-hundred day simple moving average is $8.76. The stock has a market capitalization of $81.61 million, a P/E ratio of -0.11 and a beta of 16.05.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.38) earnings per share for the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%. The company had revenue of $2.68 million for the quarter. Sell-side analysts expect that KindlyMD will post -16.8 earnings per share for the current fiscal year.

Insider Buying and Selling at KindlyMD

In other KindlyMD news, CEO David F. Bailey acquired 55,115 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were purchased at an average cost of $5.62 per share, for a total transaction of $309,746.30. Following the transaction, the chief executive officer owned 3,175,476 shares in the company, valued at $17,846,175.12. This represents a 1.77% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders purchased 191,448 shares of company stock valued at $992,908. 24.49% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On KindlyMD

A number of hedge funds and other institutional investors have recently made changes to their positions in NAKA. SG Americas Securities LLC bought a new stake in KindlyMD in the fourth quarter valued at $61,000. Virtu Financial LLC purchased a new position in KindlyMD during the 4th quarter valued at $151,000. J. Derek Lewis & Associates Inc. bought a new position in KindlyMD in the 4th quarter worth $167,000. Truist Financial Corp bought a new position in KindlyMD in the 4th quarter worth $176,000. Finally, Waddell & Associates LLC purchased a new stake in shares of KindlyMD in the 4th quarter worth about $201,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.